Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Emond

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|August 17, 2022
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United StatesJinan Liu, Bruno Emond, Eric M Maiese, et al.
Journal of Managed Care & Specialty Pharmacy|September 11, 2024
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancerChristine M Bestvina, Dexter Waters, Laura Morrison, et al.
Patient Preference and Adherence|August 29, 2023
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic LeukemiaXiaoxiao Lu, Bruno Emond, Laura Morrison, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2022
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databasesMarco Mesa-Frias, Carmine Rossi, Bruno Emond, et al.
BMC Endocrine Disorders|June 10, 2017
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitorsCarol H Wysham, Patrick Lefebvre, Dominic Pilon, et al.
Journal of Comparative Effectiveness Research|April 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databasesKerry A Rogers, Benyam Muluneh, Zaina P Qureshi, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2016
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology PracticesEsprit Ma, Vijayveer Bonthapally, Anita Chawla, et al.
Epilepsia Open|December 11, 2019
Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complexMenno Vergeer, Wendela L de Ranitz-Greven, Maureen P Neary, et al.
Journal of Health Economics and Outcomes Research|October 31, 2024
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder CancerFranklin D Gaylis, Bruno Emond, Ameur M Manceur, et al.
Journal of Medical Economics|March 18, 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settingsMurali Janakiram, Lin Fan, Sabyasachi Ghosh, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|August 17, 2022
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United StatesJinan Liu, Bruno Emond, Eric M Maiese, et al.
Journal of Managed Care & Specialty Pharmacy|September 11, 2024
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancerChristine M Bestvina, Dexter Waters, Laura Morrison, et al.
Patient Preference and Adherence|August 29, 2023
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic LeukemiaXiaoxiao Lu, Bruno Emond, Laura Morrison, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2022
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databasesMarco Mesa-Frias, Carmine Rossi, Bruno Emond, et al.
BMC Endocrine Disorders|June 10, 2017
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitorsCarol H Wysham, Patrick Lefebvre, Dominic Pilon, et al.
Journal of Comparative Effectiveness Research|April 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databasesKerry A Rogers, Benyam Muluneh, Zaina P Qureshi, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2016
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology PracticesEsprit Ma, Vijayveer Bonthapally, Anita Chawla, et al.
Epilepsia Open|December 11, 2019
Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complexMenno Vergeer, Wendela L de Ranitz-Greven, Maureen P Neary, et al.
Journal of Health Economics and Outcomes Research|October 31, 2024
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder CancerFranklin D Gaylis, Bruno Emond, Ameur M Manceur, et al.
Journal of Medical Economics|March 18, 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settingsMurali Janakiram, Lin Fan, Sabyasachi Ghosh, et al.
Pageof 8